Reduced markers of pyramidal cell integrity in the prefrontal cortex predict increased dopamine D2 receptors [94] and enhanced amphetamine-induced dopamine release [95] in patients with schizophrenia, while abnormal prefrontal activity is associated with increased presynaptic striatal dopamine in both patients [28] and individuals at clinical risk [77].